Alzheimer's Disease

Finding next generation therapies for Alzheimer's disease

Alzheimer's disease researchers Alan Palkowitz and Bruce Lamb
Older couple managing Alzheimer's disease
Researcher reviewing brain scans of an Alzheimer's disease patient

Alzheimer’s disease is a debilitating condition that takes a large toll on patients and their loved ones. Most available treatments ease the symptoms, but do not target the root cause of the disease or slow its progression. Only in the past year has there been the introduction of the first disease modifying therapies that offer new hope, however there is significant room for improvement.

By 2050, as many as 13 million people will be diagnosed with Alzheimer’s disease. The cost of providing care for them is estimated at more than one trillion dollars.

The need for new, innovative treatments is greater than ever.

In 2022, the Indiana Biosciences Research Institute (IBRI) joined the fight against Alzheimer’s disease. Our research aims to:

  • Improve understanding of the underlying mechanisms that cause the disease.
  • Discover new approaches to target the root cause of the disease. This includes Identifying novel therapies that could treat it in the early stages.
  • Explore new frontiers of precision medicine for Alzheimer’s disease where we match each person with the treatment that will be most effective for their unique disease.

Finding biomarkers for Alzheimer's disease

We’re working to identify biomarkers (biological measures like molecules, genes or proteins) that are early predictors of Alzheimer’s disease with Jeff Dage, PhD, senior research professor of neurology at the Indiana University School of Medicine. These predictors will help us:

  • Guide the development of new medicines.
  • Design more effective clinical trials.
  • Better understand who is at risk for developing Alzheimer’s disease.
  • Learn how to best match medicines to individual patients.

This research could lead to earlier interventions for the disease, as well as precision medicine approaches.

Applying the latest technologies to Alzheimer's disease research

Many advanced tools and technologies fuel our research, including:

  • Bioinformatics and computational biology to analyze human genetic and genomic data to provide disease insights.
  • Artificial intelligence, powerful computing tools, and structural biology to design and optimize potential drug molecules and study their interactions with target proteins.
  • Advanced cellular pharmacology to study the disease process in the laboratory, as well as evaluate the potential of newly designed drug molecules.
Elderly woman suffering from Alzheimer's cutting flowers in her garden.

Alzheimer’s Research

1 in 3 seniors dies with Alzheimer’s or another form of dementia

Alzheimer's Disease

“The IBRI’s focus is on enhancing our integrated capabilities and adding depth to how we approach patient-informed translational science, both independently and through valued collaborations.”

Alan Palkowitz, PhD
CEO & President

IBRI scientist working in lab

Welcome to Our Open Space Laboratories

The IBRI is a leading translational research institute that advances academic and industry science through collaboration to improve patient health outcomes.